ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

HHS Appeals Board Finds No Misconduct By Popovic

November 12, 1993

Studies Seek to Identify High-Risk Groups to Justify Mammography Screening at 40

May 4, 2012

RFAs For New Improve Accrual Of Minorities, Women

February 2, 1996

High-Dose Vitamin D With Docetaxel In Testing For Advanced Prostate Cancer

September 27, 2002

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

FDA’s Jane Henney

February 11, 1994